The U.S. drug industry has reportedly spent millions of dollars to quiet talk about rising drug prices.
According to Kaiser Health News, the Pharmaceutical Research and Manufacturers of America — also known as PhRMA — spent much of this money during last year’s election cycle. However, the group has taken “battle stations to advance its interests” ever since 2009, when it started preparing for the implementation of Obamacare.
“Does that surprise you?” said former PhRMA CEO Billy Tauzin, who headed the organization roughly a decade ago, as Obamacare got closer to becoming a reality.
He continued, stating that whenever legislators appear interested in limiting pharmaceutical prices, “PhRMA has always responded by increasing its resources.”
Members of the powerful trade organization include notable drug companies such as Johnson & Johnson, Celgene, Merck, Pfizer, Eli Lilly and Amgen.
No comments:
Post a Comment